Free Trial
NASDAQ:SPRB

Spruce Biosciences Q1 2023 Earnings Report

Spruce Biosciences logo
$0.07 -0.01 (-6.95%)
As of 09:34 AM Eastern

Spruce Biosciences EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.42
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Spruce Biosciences Revenue Results

Actual Revenue
$1.96 million
Expected Revenue
$16.00 million
Beat/Miss
Missed by -$14.04 million
YoY Revenue Growth
N/A

Spruce Biosciences Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Monday, May 15, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Spruce Biosciences' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Spruce Biosciences Earnings Headlines

Q1 EPS Estimate for Spruce Biosciences Reduced by Analyst
Spruce Biosciences (SPRB) Receives a Hold from RBC Capital
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Spruce Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spruce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spruce Biosciences and other key companies, straight to your email.

About Spruce Biosciences

Spruce Biosciences (NASDAQ:SPRB), a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

View Spruce Biosciences Profile

More Earnings Resources from MarketBeat